Olwexya (Venlafaxine)

Venlafaxine, the active ingredient in Olwexya, is a serotonin‑norepinephrine reuptake inhibitor (SNRI) presented as a oral tablet for oral use. It is prescribed for major depressive disorder and other mood‑related conditions in adults.

GNH USA supplies Olwexya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olwexya is an SNRI that acts on neurotransmitter pathways involved in mood regulation. - Major depressive disorder: alleviates depressive symptoms and improves functional outcomes. - Generalized anxiety disorder: reduces anxiety levels and associated physical symptoms. - Social anxiety disorder: helps decrease social fear and avoidance behaviours. - Panic disorder: lessens the frequency and intensity of panic attacks.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dry mouth: reduced salivation causing throat discomfort. - Insomnia: difficulty falling or staying asleep. - Dizziness: transient light‑headedness, especially on standing. - Sweating: increased perspiration without exertion. - Constipation: slowed intestinal transit.

Serious or Rare Side Effects: - Hypertensive crisis: sudden, severe elevation in blood pressure. - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperreflexia, and fever. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Severe liver injury: jaundice, elevated enzymes, or hepatic failure. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Olwexya, clinicians should consider several safety factors. - Cardiovascular assessment: evaluate blood pressure and heart rate before initiation. - Psychiatric monitoring: watch for worsening depression or emergence of suicidal thoughts. - Drug discontinuation: taper gradually to avoid discontinuation syndrome. - Pregnancy and lactation: assess risk‑benefit, as safety data are limited. - Drug interactions: review concomitant serotonergic agents. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Olwexya can interact with several medication classes, requiring careful management. Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Linezolid or rifampicin: additive serotonergic effects. - Triptans: increased serotonin activity may precipitate serotonin syndrome. Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia from serotonergic effects. - NSAIDs: heightened risk of gastrointestinal bleeding. - Diuretics: potential for enhanced hypotensive response.